Antidepressant Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Antidepressant DMPK and Bioanalytical Services

Antidepressant DMPK is shaped by a critical duality: most compounds in this class are metabolized by multiple CYP450 isoforms, but several — notably fluoxetine and paroxetine — are also potent CYP inhibitors. The analytical strategy changes fundamentally depending on whether the study objective is metabolite identification (substrate-focused) or drug-drug interaction risk assessment (inhibitor-focused).

Creative Proteomics develops antidepressant-focused DMPK workflows covering multi-CYP450 metabolism profiling, metabolite identification, CYP2D6 inhibitor risk assessment, active metabolite quantification (norfluoxetine, O-desmethylvenlafaxine, nortriptyline), microsome and hepatocyte bioanalysis, and custom multi-antidepressant panel development spanning SSRIs, SNRIs, and TCAs.

Browse Antidepressant Drug Index Request Custom Method Support

CYP Substrate vs. Inhibitor DistinctionSeparate CYP-substrate-focused workflows from inhibitor-risk-assessment workflows — fluoxetine and paroxetine require both, while most antidepressants are predominantly substrates.

Active Metabolite ContributionsAccount for pharmacologically active metabolites (norfluoxetine, O-desmethylvenlafaxine, nortriptyline) that affect PK interpretation beyond parent-drug data alone.

Multi-CYP450 ProfilingAddress metabolism across CYP2D6, CYP3A4, CYP2C19, CYP2C9, CYP1A2, and CYP2B6 — not a single-isoform problem.

Antidepressant DMPK Strategy Map SSRI · SNRI · TCA

🧬

Structural Class DecisionSSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram), SNRIs (venlafaxine, desvenlafaxine, duloxetine), or TCAs (amitriptyline) — CYP profiles differ by class.

⚡

CYP Substrate vs. Inhibitor RoleFluoxetine and paroxetine are strong CYP2D6 inhibitors in addition to being substrates; sertraline is a moderate inhibitor. Most other antidepressants are primarily substrates.

🔬

Active Metabolite TrackingNorfluoxetine (t½ ~4–16 days) from fluoxetine, O-desmethylvenlafaxine from venlafaxine, nortriptyline from amitriptyline — metabolites can dominate exposure.

📊

MetID or DDI Risk RouteMetabolite identification for substrate-focused studies; CYP inhibition assessment and DDI risk evaluation for inhibitor compounds.

Antidepressant-specific workflow design.Creative Proteomics determines whether the compound requires multi-CYP450 substrate profiling, CYP inhibition assessment, active metabolite tracking, or combined MetID+DDI evaluation before LC-MS/MS method development begins.

Antidepressant Drug Index

Find the Antidepressant Compound Behind the Study

Antidepressant studies split by a key analytical question: is the compound primarily a CYP substrate needing metabolite identification, a CYP inhibitor requiring DDI risk assessment, or both? Use the index to separate SSRIs, SNRIs, and TCAs by CYP isoform involvement, inhibitor potential, and study focus. The drug panels are intentionally concise so detailed compound monographs can be added separately.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only antidepressants matching all selected values.

9 entries · Page 1 of 3

Analytical Pain Points

What Drives Assay Failure in Antidepressant DMPK Studies?

Antidepressant DMPK can fail when all compounds are treated as a single analytical class or when only CYP substrate metabolism is considered without addressing inhibitor potential, active metabolite contributions, enantiomeric distinctions, and multi-isoform profiling needs.

Multi-CYP450 Metabolism Requires Broad Isoform Profiling

Antidepressants are metabolized across CYP2D6, CYP3A4, CYP2C19, CYP2C9, CYP1A2, and CYP2B6. Sertraline alone involves four CYP isoforms. A single-isoform assay cannot address the metabolism of even a modest antidepressant panel.

Our responseMulti-CYP450 isoform profiling with isoform-specific incubation conditions, selective inhibitors, and recombinant CYP systems covering the full antidepressant-relevant CYP range.

Metabolite Identification →

Strong CYP2D6 Inhibition Demands DDI Workflow Separation

Fluoxetine and paroxetine are strong CYP2D6 inhibitors; sertraline is a moderate inhibitor. When these compounds are the study focus, the analytical question shifts from "how is the drug metabolized?" to "does this drug alter the metabolism of co-administered compounds?"

Our responseDedicated CYP inhibition assessment workflows with probe substrates, IC₅₀ determination, and time-dependent inhibition studies separated from standard substrate-focused MetID.

DDI Assessment →

Active Metabolites Can Dominate Pharmacokinetic Profiles

Norfluoxetine has a half-life of 4–16 days and can exceed fluoxetine exposure; O-desmethylvenlafaxine is the primary active moiety; nortriptyline is an active TCA metabolite. Parent-only quantification misses the major circulating species.

Our responseSimultaneous parent-active metabolite quantification with matched internal standards, metabolite-specific calibration curves, and PK profiling that captures both parent and active metabolite exposure.

Parent-Metabolite Panels →

Racemic vs. Enantiopure Compounds Require Distinct Analytical Approaches

Citalopram is a racemic mixture; escitalopram is the S-enantiomer only. The two share CYP pathways (CYP2C19, CYP3A4, CYP2D6) but differ in potency and analytical requirements — a racemic assay is not interchangeable with an enantiopure one.

Our responseChiral and achiral LC-MS/MS method options selected according to whether the study requires racemic drug quantification or enantiopure compound analysis.

Custom LC-MS/MS Method →

Class-Spanning Panels Must Reconcile SSRIs, SNRIs, and TCAs

A single panel containing fluoxetine (SSRI, strong CYP2D6 inhibitor), venlafaxine (SNRI, CYP2D6 substrate), and amitriptyline (TCA, multi-CYP substrate) requires extraction strategies, chromatographic conditions, and MRM transitions that work across three distinct chemical subclasses.

Our responseCustom multi-antidepressant LC-MS/MS panels with extraction, chromatography, MRM transitions, internal standards, and matrix-matched calibration optimized across SSRI, SNRI, and TCA analytes.

Custom Panels →

Focused Service Paths

Four Practical Routes for Antidepressant DMPK Studies

Antidepressant workflows should be selected according to the analytical question: CYP substrate-focused metabolite identification, CYP inhibitor-focused DDI risk assessment, active metabolite-inclusive quantification, or multi-antidepressant panel development.

Parent Antidepressant Quantification

For studies requiring fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, duloxetine, amitriptyline, desvenlafaxine, or related antidepressant concentration data in biological matrices.

Single-compound antidepressant quantification
Plasma / serum / brain tissue bioanalysis
SSRI, SNRI, and TCA parent measurement
Matrix-specific concentration planning

LC-MS/MS Drug Quantification →

Antidepressant Metabolite Identification and CYP Profiling

For CYP450-mediated metabolism studies: multi-isoform profiling, Phase I metabolite identification, active metabolite confirmation, and microsome / hepatocyte incubation workflows.

Multi-CYP450 isoform profiling (CYP2D6, 3A4, 2C19, 2C9, 1A2, 2B6)
Phase I metabolite identification
Active metabolite confirmation and quantification
Microsome / hepatocyte model selection

Metabolite Identification →

CYP-Mediated DDI Risk Assessment

For studies where antidepressants act as CYP inhibitors: CYP2D6 inhibition by fluoxetine and paroxetine, CYP inhibition by sertraline, and co-medication DDI risk evaluation.

CYP isoform-specific inhibition assays
IC₅₀ determination and mechanism-based inhibition
Probe substrate incubation workflows
DDI risk evaluation and reporting

DDI Risk Assessment →

Custom Multi-Antidepressant Panel Development

For studies involving multiple antidepressants across SSRI, SNRI, and TCA classes, active metabolite inclusion, or combined substrate-inhibitor profiling.

Multi-antidepressant LC-MS/MS panels
SSRI, SNRI, and TCA compatibility
Active metabolite inclusion (norfluoxetine, O-desmethylvenlafaxine, nortriptyline)
Custom MRM and chromatographic selectivity

Custom Multi-Analyte Panels →

Project Inquiry

Need Support for a Novel or Unlisted Antidepressant?

If you are working with an SSRI, SNRI, TCA, or novel antidepressant compound — whether the study requires multi-CYP450 metabolism profiling, CYP inhibition assessment, active metabolite quantification, or a custom multi-antidepressant panel — a generic single-isoform LC-MS/MS method may not answer the study question.

Creative Proteomics develops custom LC-MS/MS and DMPK workflows by defining the structural class (SSRI/SNRI/TCA), CYP isoform involvement, inhibitor potential, active metabolite relevance, biological matrix, expected concentration range, and MetID or DDI study objective before method development begins.

Target antidepressant

SSRI / SNRI / TCA class

CYP isoforms of interest

Inhibitor potential

Active metabolite tracking

Panel requirements